- Location
secondary hyperparathyroidism
"-
OPKO Health Has Signed a Definitive Agreement to Acquire Cytochroma
Jan 14, 2013Multinational pharmaceutical and diagnostics company OPKO Health has signed a definitive agreement to acquire Cytochroma. Under the purchase, OPKO intends to include Cytochroma's Replidea and Alpharen, which are in Phase 3 clinical trials ...
Tags: OPKO Health, Cytochroma, CKD, pharmaceutical
-
KAI Pharmaceuticals Has Been Purchased by Amgen
Dec 3, 2012US based pharmaceutical company, Amgen has acquired KAI Pharmaceuticals. The acquisition, which was initially announced on 10 April 2012, includes KAI's main product KAI-4169, an agent being studied to treat secondary hyperparathyroidism ...
-
Cytochroma Announced Termination of a License Agreement with MTPC
Nov 28, 2012Cytochroma has announced termination of a license agreement with Mitsubishi Tanabe Pharma (MTPC) thereby regaining rights to all indications of lunacalcipol indications in the US and in Asian territories. The companies mutually decided to ...
Tags: Cytochroma, Mitsubishi Tanabe Pharma, lunacalcipol indications
-
Cytochroma Has Chosen Omnicomm Eclinical Suite for Phase III Studies
Aug 3, 2012Cytochroma, a clinical stage specialty pharmaceutical company, has selected OmniComm Systems' eClinical Suite of applications for its two Phase III studies. OmniComm's eClinical Suite, including the EDC, CTMS, Safety, and Coding ...
Tags: Cytochroma, clinical stage, eClinical Suite, patient data, adverse events
